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ABSTRACT 
Amongst the potential neurotoxins implicated in the pathogenesis of hepatic encephalopathy, manganese emerges as 
a new candidate. In patients with chronic liver diseases, manganese accumulates in blood and brain leading to 
pallidal signal hyperintensity on T1-weighted Magnetic Resonance (MR) Imaging. Direct measurements in globus 
pallidus obtained at autopsy from cirrhotic patients who died in hepatic coma reveal 2 to 7-fold increases of 
manganese concentration. The intensity of pallidal MR images correlates with blood manganese and with the 
presence of extrapyramidal symptoms occurring in a majority of cirrhotic patients. Liver transplantation results in 
normalization of pallidal MR signals and disappearance of extrapyramidal symptoms whereas transjugular 
intrahepatic portosystemic shunting induces an increase in pallidal hyperintensity with a concomitant deterioration 
of neurological dysfunction. These findings suggest that the toxic effects of manganese contribute to extrapyramidal 
symptoms in patients with chronic liver disease. The mechanisms of manganese neurotoxicity are still speculative, 
but there is evidence to suggest that manganese deposition in the pallidum may lead to dopaminergic dysfunction. 
Future studies should be aimed at evaluating the effects of manganese chelation and/or of treatment of the 
dopaminergic deficit on neurological symptomatology in these patients. 
Keywords: Manganese, portal systemic encephalopathy, Magnetic Resonance Imaging, globus pallidus, extrapyramidal 
disorders, portacaval shunt. 
INTRODUCTION 
The pathophysiology of hepatic encephalopathy is still not well understood despite many investigations that have 
been carried out during the last 50 years. Neurological manifestations are considered to result from a derangement 
of multiple neurotransmitter systems. Accumulation of several neurotoxic substances have been reported and it is 
likely that many of them contribute to the pathogenesis of HE. Manganese has been suggested recently as another 
candidate substance. There is increasing evidence to suggest that manganese deposition occurs in the brain (and 
more specifically in the basal ganglia) of patients with chronic liver disease and also in patients with spontaneous or 
surgically-induced portacaval shunt (PCS). 
EVIDENCE FOR BRAIN MANGANESE OVERLOAD IN CHRONIC LIVER DISEASES 
Pallidal signal hyperintensity on magnetic resonance imaging (MRI) has been observed in a majority of cirrhotic 
patients (Figure 1; Krieger et al., 1996; Pujol et al., 1993; Spahr et al., 1996). Such images could theoretically be caused 
by lipid deposition, calcification, melanin, methemoglobin or manganese. Recent autopsy studies in cirrhotic patients 
demonstrated an increased manganese content in the brain and more specifically in the pallidum (Figure 2; Krieger et 
al., 1995; Maeda et al., 1997; Pomier-Layrargues et al., 1995); in these patients, other causes for MRI pallidal 
hyperintensities had been ruled out. 
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Figure 1: Pallidal hyperintensity on T1-weighted MR image from a cirrhotic patient. Pallidal index calculated 
as the ratio of globus pallidus (1) to subcortical frontal white-matter (2) intensity was 133 (normal range: 
96 - 103). 
Further evidence suggesting that MR images result from manganese deposition is provided by observations in 
patients receiving long term parenteral nutrition where typical pallidal i mages disappeared after cessation of 
manganese supplementation (Mirowitz et al., 1991; Mirowitz et al., 1992). Prolonged inhalation of manganese dusts 
in miners produces similar MR images (Nelson et al., 1993); furthermore exposure of monkeys to manganese 
administered either by inhalation or intravenously results in selective pallidal hyperintensities on MR imaging 
(Shinotoh et al., 1995). 
 
 
 
 
 
 
 
 
Figure 2: Manganese concentrations in globus pallidus of cirrhotic patients who died in hepatic coma (•) 
and age-matched controls (C). Mean values in the cirrhotics are significantly higher than controls, p < 0.01. 
(Adapted from Pomier-Layrargues et al., 1995). 
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RELATIONSHIP BETWEEN BRAIN MANGANESE DEPOSITION AND CHRONIC LIVER DISEASE 
Average daily oral manganese intake is 2.5 - 3mg. Only 1-3% of this normally reaches the systemic circulation 
because manganese is rapidly cleared by the liver and excreted into the bile (Papavasiliou et al., 1966). Increases in 
blood manganese levels have been reported previously in cirrhotic patients (Spahr et al., 1996; Versieck et al., 1974; 
Hauser et al., 1994; Hauser et al., 1996) and it was shown that blood manganese correlated with brain MRI changes 
in patients with chronic liver disease (Figure 3). 
Potential mechanisms responsible for manganese overload include a decrease in elimination via biliary excretion 
and an increased systemic availability due to portosystemic shunting. 
Cirrhosis is associated with a variable degree of cholestasis that can diminish biliary manganese excretion. In 
addition, abnormalities of microcirculation (capillarization of the sinusoids and/or intrahepatic shunting) are 
present in a cirrhotic liver. Alternatively (or additionally) increased blood manganese in cirrhotic patients could 
result from the presence of portal-systemic collaterals produced either spontaneously or following surgical 
(portocaval anastomosis) or transjugular intra-hepatic portosystemic shunt (TIPS). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Correlation between pallidal index measured on T1-weighted MR images and blood manganese 
concentrations (r = .543; p < 0.001). (Data from Spahr et al., 1996). 
Experimental and clinical observations provide some clues to the relative importance of these potential mechanisms. 
Portosystemic shunting plays a major role. We previously observed significant correlations between blood 
manganese, pallidal hyperintensity and the presence of portal-systemic shunting in cirrhotic patients (Spahr et al., 
1996). A significant increase of pallidal hyperintensity has been reported to occur after TIPS (Krieger et al., 1997). 
Typical pallidal images were also described in a patient with patent ductus venosus (spontaneous portocaval shunt) 
in the absence of liver disease (Yanai et al., 1995) and in 6 patients with portal vein thrombosis, portal-systemic 
collaterals and a normal liver (Nolte et al., 1998). On the other hand, the important pathogenetic role of liver failure 
is illustrated by the disappearance of pallidal hyperintensity several months after liver transplantation (Pujol et al., 
1993). More recently, brain manganese accumulation was observed in a rat model of cholestatic cirrhosis as well as 
in rats with end-to-side portacaval shunt but with a normal liver (Rose et al., 1997). 
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RELATIONSHIP BETWEEN BRAIN MANGANESE ACCUMULATION AND NEUROLOGICAL 
SYMPTOMS IN CIRRHOTIC PATIENTS 
Manganese neurotoxicity had previously been reported in miners after a prolonged exposure to manganese dust, 
resulting in extrapyramidal symptoms resembling Parkinson's disease (Yamada et al., 1986). In cirrhotic patients a 
high incidence of extrapyramidal symptoms is observed when a detailed and careful neurological evaluation is 
performed (Spahr et al., 1996). Moreover, anatomical or functional lesions in the pallidum might induce cognitive 
deficits which are part of the clinical spectrum of neurological symptoms associated with hepatic encephalopathy 
(Iregren, 1994; Mergler and Baldwin, 1997). 
The question then arises as to whether pallidal manganese accumulation in cirrhotic patients might be related to the 
occurrence of neurological dysfunction in these individuals. Studies attempting to correlate neurological symptoms 
with MR imaging used as an index of brain manganese content have so far yielded conflicting results (Krieger et al., 
1996; Kulisevsky et al., 1992; Spahr et al., 1996; Spahr et al., 1998; Taylor-Robinson et al., 1995; Weissenborn et al., 
1995). This is not surprising because MRI provides only a semi-quantitative estimate of brain manganese 
concentration. Unfortunately, in vivo measurement of brain manganese is impossible to perform. An interesting 
alternative to evaluate the pathophysiological significance of brain manganese deposits would be to evaluate the 
influence of changes in liver function (before and after liver transplantation) or the degree of portosystemic shunting 
(before and after TIPS) on both neurological status and MR signal intensities. Accordingly it has been demonstrated 
that, several months after liver transplantation, neurological dysfunction improved or normalised and that MR 
pallidal hyperintensity disappeared (Devenyi et al., 1994, Pujol et al., 1993). More recently, it has been shown that, 
after the placement of an intrahepatic shunt, pallidal hyperintensity and neurological impairment worsened in a 
population of cirrhotic patients treated with this procedure compared to a control group (Krieger et al., 1997). 
There are also similarities between the neuropathologic lesions observed in the brains of monkeys and humans 
intoxicated with manganese (Yamada et al., 1996) and the brains of cirrhotic patients who died with hepatic 
encephalopathy (Butterworth et al., 1987); Alzheimer type II changes have been observed in both circumstances and 
were predominant present in basal ganglia. 
To summarize, increasing evidence supports a pathophysiologic link between brain manganese accumulation and 
the onset of neurological dysfunction in cirrhotic patients. However, the mechanisms of manganese neurotoxicity are 
still speculative. 
It has been suggested that manganese might influence dopaminergic neurotransmission. Chronic inhalation of 
manganese in primates results in a 60-80% increase in pallidal manganese and in concomitantly reduced dopamine 
concentrations (Bird et al., 1984). Other studies have demonstrated that manganese stimulates dopamine release 
from nerve endings (Drapeau and Machshev, 1984) and displaces dopamine from its storage sites (Lista et al., 1986). 
Chronic manganese administration causes increased activity of the monoamine-degrading enzyme monoamine 
oxidase (MAO) in brain (Subhash and Padmashree, 1990, Leung et al., 1986). Increased activities of both MAOA and 
MAOB isoforms have been described in autopsied brain tissue from cirrhotic patients who died in hepatic coma 
(Raghavendra Rao et al., 1993) and a selective loss of binding sites for the dopamine D2 receptor ligand 3H spiperone 
has been observed in pallidum of cirrhotic patients (Bergeron et al., 1989). 
A number of other mechanisms for manganese neurotoxicity have been suggested (Aschner et al., 1991): alterations 
of membrane fluidity, interference with enzymatic function in the CNS (such as glutamine synthetase, cytochrome 
P450-dependent drug hydroxylation activity, calmodulin-related Ca2+-ATPase activity), inhibition of [H3]-kainic acid, 
a glutamate receptor ligand, to forebrain membranes and the creation of oxidative stress following manganese 
accumulation within the mitochondria. 
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CONCLUSIONS AND PERSPECTIVES FOR THE FUTURE 
There is evidence to suggest that chronic liver insufficiency and portosystemic shunting results in accumulation of 
manganese in the brain and particularly in the basal ganglia. The pathophysiological significance of this region-
selective manganese deposition remains to be established. 
There is a poor relationship between cognitive abnormalities associated with hepatic encephalopathy and brain 
manganese overload; however the occurrence of extrapyramidal disorders is increasingly recognized in cirrhotic 
patients and there is a rational basis to hypothesize a relationship between manganese accumulation in basal ganglia 
and the presence of certain cognitive and motor symptoms. Clearly, further studies are needed to address these 
issues. If neurotoxic effects of manganese are clearly established in the future, chelation therapy could be tried in the 
hope of removing manganese and improving neurological dysfunction in patients with chronic liver diseases. 
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